Reports
Reports
Sale
The global epigenomics market is expected to grow at a CAGR of 13.1% during the forecast period of 2024-2032, driven by the rising prevalence of chronic diseases and genetic conditions, and the increasing need for research and development to explore enhanced treatment alternatives for diseases and conditions.
Modern techniques enable scientists to study epigenetic changes across entire genomes and determine how and where such changes occur. Scientists seek a better understanding of the occurrence of epigenetic changes and their consequences. Further, by identifying patterns of methylation tags across the whole genome and of histone modifications in various kinds of cells and tissues, it would be possible for scientists to recognize "signatures" associated with certain biological processes or disease states. North America, Europe and Asia are expected to be key markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Epigenomics refers to the study of the epigenome – a host of chemical compounds directing the functioning genome as a whole. These compounds attach to the DNA to activate or deactivate particular genes in the genome, changing its behaviour. Thus, the epigenome may influence regulation of protein production in some cells of the body. Researchers monitor locations and understand the functions of all the chemical tags marking the genome. When epigenomic compounds bind to DNA and alter its function, it is said that these compounds have "marked" the genome. While these marks do not change the DNA sequence, they alter the way cells use the DNA's instructions. The marks are occasionally passed on from cell to cell as cells divide. These also can be passed down from generation to generation.
There are trillion of cells in a human being; these cells have specific functions in the muscles, bones and brain, and each cell contains fundamentally the same genome in its nucleus. The way and when the different gene sets are turned on or off in different types of cells determine differences among cells. For example, specific cells in the eye turn on genes producing proteins that may detect light; particular cells in red blood cells produce proteins carrying oxygen from the air to the rest of the body. The epigenome regulates several of these changes to the genome. The epigenome is the group of chemical modifications to the DNA and DNA-associated proteins in the cell, altering gene behaviour, and are heritable (through meiosis and mitosis). The modifications take place as a natural process of development and tissue differentiation, and may be changed in response to environmental exposures or disease.
The first type of mark, known as DNA methylation, directly influences the DNA in a genome. In the process, proteins bind chemical tags called methyl groups to the bases of the DNA molecule in particular places. The methyl groups turn genes on or off by influencing interactions between the DNA and other proteins. Thus, cells can remember which genes are on or off. The second type of mark, called histone modification, influences DNA indirectly. DNA in cells is wrapped around histone proteins, forming spool-like structures enabling DNA's very long molecules to be coiled up neatly into chromosomes within the cell nucleus. Proteins can bind several chemical tags to histones. Other proteins in cells can identify these tags and decide whether that region of DNA should be used or ignored in the cell.
Lifestyle and environmental factors (which include smoking, diet and infectious disease) could expose an individual to pressures that induce chemical responses. These responses, in turn, could cause changes in the epigenome; some changes could be damaging. Cancers could be caused by changes in the genome, the epigenome, or both. Changes in the epigenome could switch on or off genes engaged in cell growth or the immune response, causing uncontrolled growth (a sign of cancer), or leading to a failure of the immune system to destroy tumours.
In cases of glioblastoma (a kind of brain tumour), the drug temozolomide has been used with some success; the drug kills cancer cells by attaching methyl groups to DNA. In some cases, methylation shows another positive – it blocks a gene that counteracts temozolomide. Patients with glioblastoma who have tumours with such methylated genes are more likely to respond to temozolomide as compared to those with unmethylated genes. Changes in the epigenome could also trigger growth-promoting genes in colon cancer, stomach cancer, and the most common type of kidney cancer. In some other types of cancer, changes in the epigenome stifle genes that generally help regulate cell growth.
Several research groups are engaged in an attempt to characterize the epigenome, and recognize, catalogue, and understand genome-wide DNA methylation patterns of all human genes in all key tissues. Such associations are multinational and multidisciplinary, and characterize the highest quality of research. Epigenomics, as a domain, has the potential to examine and reveal nongenetic components of complex diseases. It is hoped that with full genome sequence and epigenomic maps of the DNA methylation and modified histone landscapes, it would be possible to identify the exact genes that activated, and in which tissues. Such information would provide new ways to diagnose and treat complex diseases, and is expected to drive the global epigenomics market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By technology, the global epigenomics market is segmented into:
By product type, the market is divided into:
By application, the market is classified into:
By region, the market is segmented into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global epigenomics market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Technology |
|
Breakup by Application |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Epigenomics Market Overview
3.1 Global Epigenomics Market Historical Value (2017-2023)
3.2 Global Epigenomics Market Forecast Value (2024-2032)
4 Global Epigenomics Market Landscape
4.1 Global Epigenomics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Epigenomics Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Product Type
4.2.3 Analysis by Application
5 Global Epigenomics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Epigenomics Market Segmentation
6.1 Global Epigenomics Market by Product Type
6.1.1 Market Overview
6.1.2 Kits
6.1.3 Reagents
6.1.4 Enzymes
6.1.5 Services
6.2 Global Epigenomics Market by Technology
6.2.1 Market Overview
6.2.2 Histone Methylation
6.2.3 Large Non-Coding RNA
6.2.4 MicroRNA Modification
6.2.5 DNA Methylation
6.2.6 Chromatin Structures
6.2.7 Others
6.3 Global Epigenomics Market by Application
6.3.1 Market Overview
6.3.2 Diagnostics
6.3.3 Pharmaceuticals
6.4 Global Epigenomics Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Pharmaceuticals and Biotechnology Companies
6.4.4 Academic and Research Institutes
6.4.5 Others
6.5 Global Epigenomics Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Epigenomics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Epigenomics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Epigenomics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Epigenomics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Epigenomics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
18 Supplier Landscape
18.1 Epigenomics AG
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Illumina, Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Merck KGaA
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Zymo Research Corporation
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Agilent Technologies, Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Thermo Fisher Scientific
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 PacBio (US)
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Abcam plc (UK)
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Bio-Rad Laboratories
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Novartis AG
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Global Epigenomics Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The global epigenomics market size is anticipated to grow at a CAGR of 13.1% during the forecast period of 2024-2032, driven by the rising need to study complex diseases.
The major drivers of the market include the increasing shift towards personalised medicines, rising prevalence of diseases such as cancer, decreasing sequencing costs, increasing research activity, and growing applications of epigenetics in non-oncology diseases.
The growing need to study complex diseases and increased funding for research in the field of epigenomics are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The various technologies involved in the market are histone methylation, large non-coding RNA, microRNA modification, DNA methylation, and chromatin structures, among others.
Based on product type, the market is segmented into kits, reagents, and enzymes, among others.
The significant applications of the market are diagnostics and pharmaceuticals.
The major players in the industry include Epigenomics AG, Illumina, Inc., Merck KGaA, Zymo Research Corporation, and Agilent Technologies, Inc., among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.